Biocon Group on Business Outlook

The video discusses the company's quarterly results, highlighting growth in biosimilars and contract services, while addressing concerns over potential US tariffs on pharmaceuticals. It examines budget measures impacting the business, such as duty exemptions and GST reductions. The company outlines its strategy for the obesity drug portfolio, focusing on Lira Glutide and semaglutide. Upcoming product launches in biosimilars and monoclonal antibodies are also covered, with a focus on the US market and global expansion.

What is the significance of the obesity portfolio for the company?

What new product launches are expected in the biosimilars business?

How is the company planning to address the transition from pilot studies to larger scale projects?